Abstract
The efficacy of antibacterial molecules depends on their capacity to reach inhibitory concentrations in the vicinity of their target. This is particularly challenging for drugs directed against Gram-negative bacteria, which have a complex envelope comprising two membranes and efflux pumps. Precise determination of the bacterial drug content is an essential prerequisite for drug development. Here we describe three approaches that have been developed in our laboratories to quantify drugs accumulated in intact cells by spectrofluorimetry, microspectrofluorimetry, and kinetics microspectrofluorimetry (KMSF). These different procedures provide complementary results that highlight the contribution of membrane-associated mechanisms, including influx through the outer membrane (OM) and efflux, and the importance of the physicochemical properties of the transported drugs for the intracellular concentration of a given antibiotic in a given bacterial population. The three key stages of this protocol are preparation of the bacterial strains in the presence of the antibiotic; preparation of the whole-cell lysates (WCLs) and fluorescence readings; and data analysis, including normalization and quantitation of the intracellular antibiotic fluorescence relative to the internal standard and the antibiotic standard curve, respectively. Fluorimetry is limited to naturally fluorescent or labeled compounds, but in contrast to existing alternative methods such as mass spectrometry, it uniquely allows single-cell analysis. From culture growth to data analysis, the protocol described here takes 5 d.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A framework for dissecting affinities of multidrug efflux transporter AcrB to fluoroquinolones
Communications Biology Open Access 06 October 2022
-
Cephalosporin translocation across enterobacterial OmpF and OmpC channels, a filter across the outer membrane
Communications Biology Open Access 05 October 2022
-
Tolerance engineering in Deinococcus geothermalis by heterologous efflux pumps
Scientific Reports Open Access 19 February 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout




References
Boucher, H.W. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1–12 (2009).
US Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. CDC.gov https://www.cdc.gov/drugresistance/threat-report-2013/index.html (2013).
O'Neill, J. Tackling a Crisis for the Health and Welfare of Nations (Review on Antimicrobial Resistance, London, 2014).
World Health Organization, Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline, Including Tuberculosis WHO, (2017).
Stavenger, R.A. & Winterhalter, M. TRANSLOCATION project: how to get good drugs into bad bugs. Sci. Transl. Med. 6, 228ed7 (2014).
O'Shea, R. & Moser, H.E. Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem. 51, 2871–2878 (2008).
Brown, D.G. et al. Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. J. Med. Chem. 57, 10144–10161 (2014).
Page, M.G.P. & Bush, K. Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising? Curr. Opin. Pharmacol. 18, 91–97 (2014).
Payne, D.J et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29–40 (2007).
Boucher, H.W. et al. 10 × ′20 Progress—development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 56, 1685–1694 (2013).
Zgurskaya, H.I., López, C.A. & Gnanakaran, S. Permeability barrier of Gram-negative cell envelopes and approaches to bypass it. ACS Infect. Dis. 1, 512–522 (2015).
Krishnamoorthy, G. et al. Breaking the permeability barrier of Escherichia coli by controlled hyperporination of the outer membrane. Antimicrob. Agents Chemother. 60, 7372–7381 (2016).
Nikaido, H., Rosenberg, E.Y. & Foulds, J. Porin channels in Escherichia coli: studies with beta-lactams in intact cells. J. Bacteriol. 153, 232–240 (1983).
Yoshimura, F. & Nikaido, H. Diffusion of beta-lactam antibiotics through the porin channels of Escherichia coli K-12. Antimicrob. Agents Chemother. 27, 84–92 (1985).
Nikaido, H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob. Agents Chemother. 33, 1831–1836 (1989).
Hancock, R.E. The bacterial outer membrane as a drug barrier. Trends Microbiol. 5, 37–42 (1997).
Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67, 593–656 (2003).
Pagès, J.-M., James, C.E. & Winterhalter, M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat. Rev. Microbiol. 6, 893–903 (2008).
Kojima, S. & Nikaido, H. Permeation rates of penicillins indicate that Escherichia coli porins function principally as nonspecific channels. Proc. Natl. Acad. Sci. USA 110, E2629–E2634 (2013).
Silver, L.L. A Gestalt approach to Gram-negative entry. Bioorg. Med. Chem. 24, 6379–6389 (2016).
Masi, M. et al. Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria. Nat. Microbiol. 2, 17001 (2017).
Nikaido, H. & Pagès, J.-M. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol. Rev. 36, 340–363 (2012).
Li, Z.H., Plesiat, P. & Nikaido, H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 28, 337–418 (2015).
Nagano, K. & Nikaido, H. Kinetic behavior of the major multidrug efflux pump AcrB of Escherichia coli. Proc. Natl. Acad. Sci. USA 106, 5854–5858 (2009).
Lim, S.P. & Nikaido, H. Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli. Antimicrob. Agents Chemother. 54, 1800–1806 (2010).
Davin-Regli, A. et al. Membrane permeability and regulation of drug “influx and efflux” in enterobacterial pathogens. Curr. Drug Targets 9, 750–759 (2008).
Blair, J.M. et al. Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 13, 42–51 (2015).
Blair, J.M. & Piddock, L.J. How to measure export via bacterial multidrug resistance efflux pumps. MBio 7, e00840-16 (2016).
Kašˇáková, S. et al. Antibiotic transport in resistant bacteria: synchrotron UV fluorescence microscopy to determine antibiotic accumulation with single cell resolution. PLoS One 7, e38624 (2012).
Pagès, J.-M. et al. New peptide-based antimicrobials for tackling drug resistance in bacteria: single-cell fluorescence imaging. ACS Med. Chem. Lett. 4, 556–559 (2013).
Cinquin, B. et al. Microspectrometric insights on the uptake of antibiotics at the single bacterial cell level. Sci. Rep. 5, 17968 (2015).
Allam, A. et al. Microspectrofluorimetry to dissect the permeation of ceftazidime in Gram-negative bacteria. Sci. Rep. 7, 986 (2017).
Vergalli, J. et al. Fluoroquinolone structure and translocation flux across bacterial membrane. Sci. Rep. 7, 9821 (2017).
Ritchie, K. et al. Single-molecule imaging in live bacteria cells. Philos. Trans. R. Soc. Lond. B Biol. Sci. 368, 20120355 (2012).
Deris, Z.Z. et al. Probing the penetration of antimicrobial polymyxin lipopeptides into Gram-negative bacteria. Bioconjug. Chem. 25, 750–760 (2014).
Chileveru, H.R. et al. Visualizing attack of Escherichia coli by the antimicrobial peptide human defensin 5. Biochemistry 54, 1767–1777 (2015).
Phetsang, W. et al. Fluorescent trimethoprim conjugate probes to assess drug accumulation in wild type and mutant Escherichia coli. ACS Infect. Dis. 2, 688–701 (2016).
Davis, T.D., Gerry, C.J. & Tan, D.S. General platform for systematic quantitative evaluation of small-molecule permeability in bacteria. ACS Chem. Biol. 9, 2535–2344 (2014).
Richter, M.F. et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 545, 299–304 (2017).
Westfall, D.A. et al. Bifurcation kinetics of drug uptake by Gram-negative bacteria. PLoS One 12, e0184671 (2017).
Zgurskaya, H.I. & Nikaido, H. Bypassing the periplasm: reconstitution of the AcrAB multidrug efflux pump of Escherichia coli. Proc. Natl. Acad. Sci. USA 96, 7190–7195 (1999).
Winterhalter, M. & Ceccarelli, M. Physical methods to quantify small antibiotic molecules uptake into Gram-negative bacteria. Eur. J. Pharm. Biopharm. 95, 63–67 (2015).
Picard, M. et al. Biochemical reconstitution and characterization of multicomponent drug efflux transporters. Methods Mol. Biol. 1700, 113–145 (2018).
Joos, B et al. Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob. Agents Chemother. 27, 353–356 (1985).
Morton, S.J., Shull, V.H. & Dickn, J.D. Determination of norfloxacin and ciprofloxacin concentrations in serum and urine by high-pressure liquid chromatography. Antimicrob. Agents Chemother. 30, 325–327 (1986).
Chapman, J.S. & Georgopapadakou, N.H. Fluorometric assay for fleroxacin uptake by bacterial cells. Antimicrob. Agents Chemother. 33, 27–29 (1989).
Mortimer, P.G. & Piddock, L.J. The accumulation of five antibacterial agents in porin-deficient mutants of Escherichia coli. J. Antimicrob. Chemother. 32, 195–213 (1993).
Piddock, L.J et al. Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. J. Antimicrob. Chemother. 43, 61–70 (1999).
Ricci, V. & Piddock, L.J. Accumulation of norfloxacin by Bacteroides fragilis. Antimicrob. Agents Chemother. 44, 2361–2366 (2000).
Piddock, L.J. & Ricci, V. Accumulation of five fluoroquinolones by Mycobacterium tuberculosis H37Rv. J. Antimicrob. Chemother. 48, 787–791 (2001).
Piddock, L.J. & Johnson, M.M. Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46, 813–820 (2002).
Bolla, J.-M. et al. Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria. FEBS Lett. 585, 1682–1690 (2011).
Bassetti, M. & Righi, E. New antibiotics and antimicrobial combination therapy for the treatment of Gram-negative bacterial infections. Curr. Opin. Crit. Care 21, 402–411 (2015).
Brown, D. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? Nat. Rev. Drug Discov. 14, 821–832 (2015).
Wright, G.D. Antibiotic adjuvants: rescuing antibiotics from resistance. Trends Microbiol. 24, 862–871 (2016).
González-Bello, C. Antibiotic adjuvants—a strategy to unlock bacterial resistance to antibiotics Bioorg. 27, 4221–4228 (2017).
Haynes, K.M. et al. Identification and structure-activity relationships of novel compounds that potentiate the activities of antibiotics in Escherichia coli. J. Med. Chem. 60, 6205–6219 (2017).
Jamme, F. et al. Synchrotron UV fluorescence microscopy uncovers new probes in cells and tissues. Microsc. Microanal. 16, 507–514 (2010).
Batard, E. et al. Diffusion of ofloxacin in the endocarditis vegetation assessed with synchrotron radiation UV fluorescence microspectroscopy. PLoS One 6, e19440 (2011).
Jamme, F. et al. Deep UV autofluorescence microscopy for cell biology and tissue histology. Biol. Cell 105, 277–828 (2013).
Bauer, J. et al. A combined pharmacodynamics quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob. Agents Chemother. 57, 2726–2737 (2013).
Boudjemaa, R. et al. New insight into daptomycin bioavailability and localization in Staphylococcus aureus biofilms by dynamic fluorescence imaging. Antimicrob. Agents Chemother. 60, 4983–4990 (2016).
Pienaar, E. et al. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach. PLoS Comput. Biol. 13, e1005650 (2017).
Pradel, E. & Pagès, J.-M. The AcrAB-TolC efflux pump contributes to multidrug resistance in the nosocomial pathogen Enterobacter aerogenes. Antimicrob. Agents Chemother. 46, 2640–2643 (2002).
George, A.M. & Levy, S.B. Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: involvement of a non-plasmid-determined efflux of tetracycline. J. Bacteriol. 155, 531–540 (1983).
Okusu, H. et al. Efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J. Bacteriol. 178, 306–308 (1996).
Pantel, A. et al. French regional surveillance program of carbapenemase-producing Gram-negative bacilli: results from a 2-year period. Eur. J. Clin. Microbiol. Infect. Dis. 33, 2285–2292 (2014).
Philippe, N. et al. In vivo evolution of bacterial resistance in two cases of Enterobacter aerogenes infections during treatment with imipenem. PLoS One 10, e0138828 (2015).
Bornet, C. et al. Imipenem and expression of multidrug efflux pump in Enterobacter aerogenes. Biochem. Biophys. Res. Commun. 301, 985–990 (2003).
Dupont, M., James, C.E., Chevalier, J. & Pagès, J.-M. An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins. Antimicrob. Agents Chemother. 51, 3190–3198 (2007).
Acknowledgements
We are especially grateful to I. Artaud for her commitment and motivation during the development of this original approach. We also thank A. Davin-Regli, R. Stavenger and M. Winterhalter for their fruitful discussions, and A.-M. Tran, V. Rouam and B. Pineau for technical assistance. The research leading to these results was conducted as part of the TRANSLOCATION consortium, and it has received support from the Innovative Medicines Initiatives Joint Undertaking under Grant Agreement no. 115525, resources that are composed of financial contribution from the European Union's seventh framework program (FP7/2007–2013), and EFPIA companies in kind contribution. J.V., E.D., J.P., B.C., L.M., and M.M. are funded by IMI-Translocation (grant 115525). This work was also supported by Aix-Marseille University and Service de Santé des Armées, and by Soleil program (project nos. 20130061, 20130949, 20140047, 20141262, 20150318, 20151274, and 20160173).
Author information
Authors and Affiliations
Contributions
J.V., E.D., J.P., B.C., L.M., M.M., M.R. and J.-M.P. all contributed equally to manuscript writing.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Vergalli, J., Dumont, E., Pajović, J. et al. Spectrofluorimetric quantification of antibiotic drug concentration in bacterial cells for the characterization of translocation across bacterial membranes. Nat Protoc 13, 1348–1361 (2018). https://doi.org/10.1038/nprot.2018.036
Published:
Issue Date:
DOI: https://doi.org/10.1038/nprot.2018.036
This article is cited by
-
A framework for dissecting affinities of multidrug efflux transporter AcrB to fluoroquinolones
Communications Biology (2022)
-
Cephalosporin translocation across enterobacterial OmpF and OmpC channels, a filter across the outer membrane
Communications Biology (2022)
-
Tolerance engineering in Deinococcus geothermalis by heterologous efflux pumps
Scientific Reports (2021)
-
An LC-MS/MS assay and complementary web-based tool to quantify and predict compound accumulation in E. coli
Nature Protocols (2021)
-
Defining new chemical space for drug penetration into Gram-negative bacteria
Nature Chemical Biology (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.